Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma

30 Mar 2011

Abstract excerpt

BACKGROUND: Gemcitabine is a promising drug for cholangiocarcinoma treatment. However, the kinetics and metabolism of this drug in cholangiocarcinoma treatment are not well defined. We aimed to investigate the potential clinical role of gemcitabine metabolism-related genes in the gemcitabine sensitivity of cholangiocarcinoma and identify and characterize novel gemcitabine resistance-related genes. METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone health and treatments
Share to Cholangiocarcinoma and Gallbladder Cancer Studies
Share to Colorectal Cancer Treatments and Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21451941
DOI: 10.1007/s00534-011-0376-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinomaPMID 21451941Read ↗

A 14-gene gemcitabine resistance gene signature is significantly associated with the prognosis of pancreatic cancer patientsSemantic proximity Read ↗

Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line Resistant to GemcitabineSemantic proximity Read ↗

Proteomics and Bioinformatics Identify Drug-Resistant-Related Genes with Prognostic Potential in CholangiocarcinomaSemantic proximity Read ↗

miR-29b, miR-205 and miR-221 Enhance Chemosensitivity to Gemcitabine in HuH28 Human Cholangiocarcinoma CellsSemantic proximity Read ↗

MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cellsSemantic proximity Read ↗

Role of the long non-coding RNAs in regulation of Gemcitabine response in tumor cellsSemantic proximity Read ↗

Microarray analysis of circular RNA expression profiles associated with gemcitabine resistance in pancreatic cancer cellsSemantic proximity Read ↗

ERAP2 as a potential biomarker for predicting gemcitabine response in patients with pancreatic cancerSemantic proximity Read ↗

Effect of ribonucleotide reductase M1 expression on overall survival in patients with pancreatic cancer receiving gemcitabine chemotherapy: A literature‐based meta‐analysisSemantic proximity Read ↗

Multidrug resistance genes screening of pancreatic cancer based on sensitivity profile to chemotherapeutic drugsSemantic proximity Read ↗

Array analysis for potential biomarker of gemcitabine identification in non-small cell lung cancer cell lines.Semantic proximity Read ↗

Long non-coding RNA LINC00665 promotes gemcitabine resistance of Cholangiocarcinoma cells via regulating EMT and stemness properties through miR-424-5p/BCL9L axisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.